The patent, which was granted in March 2009, covers the use of a specific polymer for the prophylactic and therapeutic treatment of rhinovirus infections.
Andreas Grassauer, CEO and co-founder of Marinomed, said: “We are delighted that this first patent has been granted. This is the first of several patent applications that were filed in order to protect our intellectual property around products for the treatment of respiratory viruses.”
The company’s first product, the anti-viral nasal spray Coldamaris prophylactic which contains Carragelose, was launched in 2008 for the prevention of and treatment of the common cold and viral-induced respiratory infections.